WILLIS® Granted Market Approval in Thailand

Bangkok, Thailand - WILLIS® Intracranial Stent Graft System ("WILLIS®"), a neurovascular product in-house developed by MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech"), was recently granted market approval from Thailand Food and Drug Administration. It is the first registration certificate MicroPort® NeuroTech gained in the overseas market, marking an important step forward in exploring the international markets.
WILLIS® is the first stent graft system launched in China for the treatment of intracranial aneurysms, and is the first product in China that adopts the design of vascular reconstruction. It is composed of the stent and delivery system. With the procedure of vascular reconstruction, WILLIS® achieves complete occlusion of intracranial aneurysms, keeps the parental artery open, and leads to recovery in hemodynamics of the lesion area to achieve vascular reconstruction so as to attain the effect of treating aneurysm.
Intracranial aneurysm is a cerebrovascular disorder in which weakness in the wall of a cerebral artery or vein causes a localized dilation or ballooning of the blood vessel. The disease is regarded as a bomb ticking in brain to explode at any time, with incidence as high as 2% to 4% in people aged between 40 and 60. If an intracranial aneurysm ruptures, the fatality is 40% and the disability rate is 33%. Compared with the traditional method of stent-assisted coil embolization treatment, the procedure of vascular reconstruction using WILLIS® features small occupied effect, reduced risk of reoccurrence, and lower treatment cost, as it effectively shunt the blood flow and keep it off of the aneurysm wall, which leads to thrombosis in the Intracranial aneurysm. With WILLIS®, patients suffering from wide-necked, giant, or ruptured aneurysms or pseudoaneurysms can receive better treatment effect.